How Do Clinicians Understand Ozempic-Related Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Guidance

If you are experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis—a condition where the stomach empties too slowly. Decades of pharmacovigilance have documented similar gastrointestinal effects with GLP-1 receptor agonists, and this page explains how clinicians currently frame the risk, diagnosis, and monitoring of Ozempic-associated gastroparesis.

Understanding Gastroparesis and Its Connection to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or, in severe cases, surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes. Its pharmacology involves slowing gastric emptying, which contributes to glucose control by reducing postprandial glucose excursions. However, this mechanism also underlies its gastrointestinal adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% with Ozempic 0.5 mg, 36.4% with Ozempic 1 mg, and 34.0% with Ozempic 2 mg, compared to 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for 0.5 mg and 3.8% for 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Beyond nausea and vomiting, Ozempic has been associated with other gastrointestinal adverse reactions occurring at frequencies below 5%, including dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0% placebo, 2.7% 0.5 mg, 1.1% 1 mg), flatulence (0.8% placebo, 0.4% 0.5 mg, 1.5% 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% 0.5 mg, 1.5% 1 mg), and gastritis (0.8% placebo, 0.8% 0.5 mg, 0.4% 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate that Ozempic can induce a spectrum of upper gastrointestinal symptoms that overlap with those of gastroparesis.

Mechanistic Link and Warning Adequacy

The mechanistic pathway linking Ozempic to gastroparesis is rooted in its action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and their activation slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. While this effect is intended to improve glycemic control, it can become pathological in susceptible individuals, leading to clinically significant delayed gastric emptying. The label does not explicitly list gastroparesis as an adverse reaction, but the reported gastrointestinal adverse reactions, including dyspepsia and gastroesophageal reflux disease, are consistent with gastroparesis symptoms. The absence of a specific warning for gastroparesis raises questions about the adequacy of warnings provided to patients and prescribers. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a central concern. The label includes a section on hypersensitivity reactions, noting that serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, it does not specifically warn about the risk of gastroparesis. Given the known pharmacological effect of delayed gastric emptying, patients who develop persistent nausea, vomiting, or abdominal pain after initiating Ozempic may not be promptly evaluated for gastroparesis. This gap in warning could delay diagnosis and treatment, potentially leading to more severe outcomes such as malnutrition, dehydration, or hospitalization.

Settlement Considerations for Virginia Patients

For affected patients in Virginia, settlement-related considerations involve documenting the timeline between Ozempic exposure and the onset of gastroparesis symptoms. Clinical trials show that gastrointestinal adverse reactions often occur during dose escalation, but the onset can vary. Patients who develop symptoms weeks to months after starting Ozempic may have a stronger causal link. Medical records should include dates of Ozempic initiation, dose changes, symptom onset, diagnostic tests (e.g., gastric emptying studies), and any treatments for gastroparesis. Legal claims may hinge on whether the manufacturer provided adequate warnings about the risk of gastroparesis and whether the patient’s harm was foreseeable. In summary, Ozempic is associated with a range of gastrointestinal adverse reactions, including those consistent with gastroparesis, due to its mechanism of slowing gastric emptying. The label does not specifically warn about gastroparesis, which may affect the adequacy of warnings for patients and prescribers. Virginia patients considering settlement should carefully document the temporal relationship between Ozempic use and the development of gastroparesis, as this evidence will be critical in establishing causation and harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

Gastroparesis is a disorder characterized by delayed gastric emptying without mechanical obstruction, causing symptoms like nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures how quickly food leaves the stomach.

How does Ozempic cause gastrointestinal side effects?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying to improve glycemic control. This mechanism can lead to gastrointestinal adverse reactions such as nausea, vomiting, dyspepsia, and gastroesophageal reflux disease, which overlap with gastroparesis symptoms. Clinical trials show higher rates of these effects compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What should Virginia patients document for a potential settlement?

Patients should document the timeline of Ozempic use, including start dates, dose changes, onset of symptoms, diagnostic tests (e.g., gastric emptying studies), and treatments. This evidence is crucial to establish a causal link between Ozempic and gastroparesis for legal claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.